Related Experiment Videos
Monosialoganglioside GM1 in cerebral ischemia
A Carolei1, C Fieschi, R Bruno
1Istituto di Scienze Neurologiche, Università degli Studi di Siena, Italy.
Cerebrovascular and Brain Metabolism Reviews
|January 1, 1991
Summary
Monosialoganglioside GM1 (ganglioside monosialo-tetrahexosyl-GM1) shows promise in reducing brain injury by protecting neurons from damage and enhancing recovery. Further clinical studies are needed to confirm its therapeutic benefits in humans.
Area of Science:
- Neuroscience
- Pharmacology
- Neuroprotection
Background:
- Excitatory amino acids can cause neurotoxicity.
- Monosialoganglioside GM1 (GM1) may counteract this neurotoxicity.
- GM1 also appears to enhance neuronotrophic factors.
Purpose of the Study:
- To review the potential therapeutic efficacy of GM1 administration.
- To examine GM1's role in neuroprotection and functional recovery after brain injury.
Main Methods:
- In vitro studies demonstrating GM1's neuroprotective mechanisms.
- Review of clinical studies on GM1 efficacy in humans.
Main Results:
- GM1 limits neurotoxicity from excitatory amino acids in vitro.
- Systemic GM1 administration may reduce acute nerve cell damage and improve functional recovery.
- GM1's acute effects may involve excitotoxicity attenuation; long-term effects may involve potentiation of neuronotrophic factors.
Conclusions:
- GM1 shows potential therapeutic benefits for brain injury.
- Pioneer clinical studies suggest efficacy in humans.
- Larger, randomized, double-blind studies are required to establish definitive therapeutic efficacy.